Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.07
VRX's Cash to Debt is ranked lower than
95% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. VRX: 0.07 )
Ranked among companies with meaningful Cash to Debt only.
VRX' s 10-Year Cash to Debt Range
Min: -1.06  Med: 0.28 Max: No Debt
Current: 0.07
-1.06
No Debt
Equity to Asset 0.17
VRX's Equity to Asset is ranked lower than
94% of the 562 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. VRX: 0.17 )
Ranked among companies with meaningful Equity to Asset only.
VRX' s 10-Year Equity to Asset Range
Min: 0.17  Med: 0.52 Max: 0.85
Current: 0.17
0.17
0.85
Interest Coverage 2.10
VRX's Interest Coverage is ranked lower than
97% of the 374 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2065.49 vs. VRX: 2.10 )
Ranked among companies with meaningful Interest Coverage only.
VRX' s 10-Year Interest Coverage Range
Min: 0.12  Med: 7.28 Max: 121.91
Current: 2.1
0.12
121.91
F-Score: 6
Z-Score: 2.36
M-Score: -2.45
WACC vs ROIC
6.48%
7.31%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 26.00
VRX's Operating margin (%) is ranked higher than
89% of the 658 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. VRX: 26.00 )
Ranked among companies with meaningful Operating margin (%) only.
VRX' s 10-Year Operating margin (%) Range
Min: -9.32  Med: 22.34 Max: 45.51
Current: 26
-9.32
45.51
Net-margin (%) 11.65
VRX's Net-margin (%) is ranked higher than
70% of the 659 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.90 vs. VRX: 11.65 )
Ranked among companies with meaningful Net-margin (%) only.
VRX' s 10-Year Net-margin (%) Range
Min: -47.86  Med: 19.07 Max: 42.72
Current: 11.65
-47.86
42.72
ROE (%) 18.38
VRX's ROE (%) is ranked higher than
80% of the 685 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.19 vs. VRX: 18.38 )
Ranked among companies with meaningful ROE (%) only.
VRX' s 10-Year ROE (%) Range
Min: -59.67  Med: 13.31 Max: 88.04
Current: 18.38
-59.67
88.04
ROA (%) 3.38
VRX's ROA (%) is ranked higher than
51% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. VRX: 3.38 )
Ranked among companies with meaningful ROA (%) only.
VRX' s 10-Year ROA (%) Range
Min: -18.92  Med: 7.69 Max: 47.05
Current: 3.38
-18.92
47.05
ROC (Joel Greenblatt) (%) 46.33
VRX's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. VRX: 46.33 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VRX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -69.93  Med: 90.59 Max: 161.84
Current: 46.33
-69.93
161.84
Revenue Growth (3Y)(%) 53.40
VRX's Revenue Growth (3Y)(%) is ranked higher than
96% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. VRX: 53.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VRX' s 10-Year Revenue Growth (3Y)(%) Range
Min: -10.8  Med: 15.80 Max: 82.1
Current: 53.4
-10.8
82.1
EBITDA Growth (3Y)(%) 64.00
VRX's EBITDA Growth (3Y)(%) is ranked higher than
98% of the 483 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. VRX: 64.00 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VRX' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.7  Med: 16.60 Max: 113
Current: 64
-35.7
113
EPS Growth (3Y)(%) 83.10
VRX's EPS Growth (3Y)(%) is ranked higher than
98% of the 451 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. VRX: 83.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VRX' s 10-Year EPS Growth (3Y)(%) Range
Min: -37.1  Med: 11.10 Max: 100.6
Current: 83.1
-37.1
100.6
» VRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

VRX Guru Trades in Q3 2014

Jana Partners 1,284,184 sh (New)
Paul Tudor Jones 6,826 sh (New)
George Soros 626,748 sh (+32.73%)
Diamond Hill Capital 173,012 sh (+17.01%)
Lou Simpson 1,815,916 sh (+12.40%)
Chris Davis 3,529,237 sh (+11.91%)
Wallace Weitz 1,691,525 sh (+9.05%)
Steve Mandel 10,985,940 sh (+8.89%)
Glenn Greenberg 6,586,582 sh (+8.86%)
John Paulson 520,700 sh (+4.08%)
Ruane Cunniff 34,494,015 sh (+0.57%)
Steven Cohen 523,400 sh (unchged)
Jeff Ubben 18,923,877 sh (unchged)
Joel Greenblatt Sold Out
Private Capital 296,871 sh (-1.19%)
First Eagle Investment 1,010,802 sh (-1.33%)
Lee Ainslie 2,527,896 sh (-3.70%)
Andreas Halvorsen 9,967,690 sh (-15.75%)
Steven Cohen 1,056,700 sh (-30.87%)
Jeremy Grantham 23,705 sh (-47.96%)
Louis Moore Bacon 30,544 sh (-76.03%)
» More
Q4 2014

VRX Guru Trades in Q4 2014

Jim Simons 38,989 sh (New)
Joel Greenblatt 295,632 sh (New)
Jeremy Grantham 1,042,191 sh (+4296.50%)
Paul Tudor Jones 100,000 sh (+1364.99%)
Jana Partners 4,307,534 sh (+235.43%)
First Eagle Investment 1,191,832 sh (+17.91%)
Jeff Ubben 19,383,877 sh (+2.43%)
Jeff Ubben 19,383,877 sh (+1.30%)
John Paulson 520,700 sh (unchged)
Ruane Cunniff 34,331,973 sh (unchged)
Ruane Cunniff 34,331,973 sh (-0.47%)
Chris Davis 3,508,163 sh (-0.60%)
Diamond Hill Capital 171,513 sh (-0.87%)
Lou Simpson 1,794,227 sh (-1.19%)
Private Capital 292,802 sh (-1.37%)
George Soros 606,587 sh (-3.22%)
Lee Ainslie 2,423,766 sh (-4.12%)
Glenn Greenberg 6,126,609 sh (-6.98%)
Andreas Halvorsen 9,077,007 sh (-8.94%)
Wallace Weitz 1,378,606 sh (-18.50%)
Steve Mandel 8,250,886 sh (-24.90%)
Louis Moore Bacon 14,286 sh (-53.23%)
Steven Cohen 132,300 sh (-87.48%)
» More
Q1 2015

VRX Guru Trades in Q1 2015

Bill Ackman 19,473,933 sh (New)
Jim Simons 475,837 sh (+1120.44%)
John Paulson 2,050,000 sh (+293.70%)
Louis Moore Bacon 30,063 sh (+110.44%)
Jeremy Grantham 1,155,927 sh (+10.91%)
Lou Simpson 1,898,540 sh (+5.81%)
Diamond Hill Capital 179,505 sh (+4.66%)
Private Capital 295,320 sh (+0.86%)
Jeff Ubben 19,383,877 sh (unchged)
First Eagle Investment 1,191,832 sh (unchged)
Bill Ackman 19,473,933 sh (unchged)
Steven Cohen Sold Out
George Soros Sold Out
Ruane Cunniff 34,089,378 sh (-0.71%)
Ruane Cunniff 34,083,713 sh (-0.72%)
Glenn Greenberg 5,877,016 sh (-4.07%)
Steve Mandel 5,569,460 sh (-32.50%)
Wallace Weitz 917,261 sh (-33.46%)
Chris Davis 1,877,040 sh (-46.50%)
Lee Ainslie 1,275,861 sh (-47.36%)
Andreas Halvorsen 4,058,343 sh (-55.29%)
Jana Partners 1,571,454 sh (-63.52%)
Joel Greenblatt 65,531 sh (-77.83%)
Paul Tudor Jones 1,256 sh (-98.74%)
» More
Q2 2015

VRX Guru Trades in Q2 2015

Ken Fisher 1,828 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with VRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 96.89
VRX's P/E(ttm) is ranked lower than
82% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.90 vs. VRX: 96.89 )
Ranked among companies with meaningful P/E(ttm) only.
VRX' s 10-Year P/E(ttm) Range
Min: 5.91  Med: 16.64 Max: 660.81
Current: 96.89
5.91
660.81
Forward P/E 15.75
VRX's Forward P/E is ranked higher than
73% of the 233 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.27 vs. VRX: 15.75 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 97.30
VRX's PE(NRI) is ranked lower than
82% of the 472 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.00 vs. VRX: 97.30 )
Ranked among companies with meaningful PE(NRI) only.
VRX' s 10-Year PE(NRI) Range
Min: 5.9  Med: 16.38 Max: 631.44
Current: 97.3
5.9
631.44
P/B 13.67
VRX's P/B is ranked lower than
93% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.55 vs. VRX: 13.67 )
Ranked among companies with meaningful P/B only.
VRX' s 10-Year P/B Range
Min: 1.03  Med: 2.74 Max: 14.06
Current: 13.67
1.03
14.06
P/S 11.28
VRX's P/S is ranked lower than
82% of the 649 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.43 vs. VRX: 11.28 )
Ranked among companies with meaningful P/S only.
VRX' s 10-Year P/S Range
Min: 1.61  Med: 3.93 Max: 11.6
Current: 11.28
1.61
11.6
PFCF 53.90
VRX's PFCF is ranked lower than
55% of the 275 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 49.38 vs. VRX: 53.90 )
Ranked among companies with meaningful PFCF only.
VRX' s 10-Year PFCF Range
Min: 2.67  Med: 11.77 Max: 281.44
Current: 53.9
2.67
281.44
POCF 42.07
VRX's POCF is ranked lower than
62% of the 384 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 29.86 vs. VRX: 42.07 )
Ranked among companies with meaningful POCF only.
VRX' s 10-Year POCF Range
Min: 4.05  Med: 10.36 Max: 48.31
Current: 42.07
4.05
48.31
EV-to-EBIT 56.50
VRX's EV-to-EBIT is ranked lower than
77% of the 486 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.52 vs. VRX: 56.50 )
Ranked among companies with meaningful EV-to-EBIT only.
VRX' s 10-Year EV-to-EBIT Range
Min: -5860.4  Med: 13.70 Max: 2452.2
Current: 56.5
-5860.4
2452.2
PEG 1.74
VRX's PEG is ranked higher than
66% of the 251 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.94 vs. VRX: 1.74 )
Ranked among companies with meaningful PEG only.
VRX' s 10-Year PEG Range
Min: 0.76  Med: 1.86 Max: 249.36
Current: 1.74
0.76
249.36
Shiller P/E 4805.60
VRX's Shiller P/E is ranked lower than
100% of the 310 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 39.83 vs. VRX: 4805.60 )
Ranked among companies with meaningful Shiller P/E only.
VRX' s 10-Year Shiller P/E Range
Min: 7.85  Med: 35.40 Max: 4943.71
Current: 4805.6
7.85
4943.71
Current Ratio 5.23
VRX's Current Ratio is ranked higher than
80% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. VRX: 5.23 )
Ranked among companies with meaningful Current Ratio only.
VRX' s 10-Year Current Ratio Range
Min: 0.72  Med: 1.63 Max: 9.68
Current: 5.23
0.72
9.68
Quick Ratio 4.91
VRX's Quick Ratio is ranked higher than
81% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. VRX: 4.91 )
Ranked among companies with meaningful Quick Ratio only.
VRX' s 10-Year Quick Ratio Range
Min: 0.59  Med: 1.25 Max: 9.3
Current: 4.91
0.59
9.3
Days Inventory 150.11
VRX's Days Inventory is ranked lower than
67% of the 621 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.49 vs. VRX: 150.11 )
Ranked among companies with meaningful Days Inventory only.
VRX' s 10-Year Days Inventory Range
Min: 89.43  Med: 145.94 Max: 333.87
Current: 150.11
89.43
333.87
Days Sales Outstanding 98.42
VRX's Days Sales Outstanding is ranked lower than
68% of the 592 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.86 vs. VRX: 98.42 )
Ranked among companies with meaningful Days Sales Outstanding only.
VRX' s 10-Year Days Sales Outstanding Range
Min: 43.41  Med: 80.09 Max: 146.62
Current: 98.42
43.41
146.62

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 6.39
VRX's Price/Projected FCF is ranked lower than
70% of the 321 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.23 vs. VRX: 6.39 )
Ranked among companies with meaningful Price/Projected FCF only.
VRX' s 10-Year Price/Projected FCF Range
Min: 0.33  Med: 2.02 Max: 11.22
Current: 6.39
0.33
11.22
Price/Median PS Value 2.94
VRX's Price/Median PS Value is ranked lower than
86% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.40 vs. VRX: 2.94 )
Ranked among companies with meaningful Price/Median PS Value only.
VRX' s 10-Year Price/Median PS Value Range
Min: 0.51  Med: 1.57 Max: 5.51
Current: 2.94
0.51
5.51
Price/Peter Lynch Fair Value 3.98
VRX's Price/Peter Lynch Fair Value is ranked lower than
81% of the 148 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.08 vs. VRX: 3.98 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
VRX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67  Med: 2.43 Max: 61.66
Current: 3.98
0.67
61.66
Earnings Yield (Greenblatt) (%) 1.84
VRX's Earnings Yield (Greenblatt) (%) is ranked lower than
54% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.30 vs. VRX: 1.84 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VRX' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 0.1  Med: 6.00 Max: 20.6
Current: 1.84
0.1
20.6
Forward Rate of Return (Yacktman) (%) 72.94
VRX's Forward Rate of Return (Yacktman) (%) is ranked higher than
99% of the 308 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.88 vs. VRX: 72.94 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VRX' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 2.5  Med: 16.70 Max: 73.5
Current: 72.94
2.5
73.5

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:VRX.Canada, BVF.Germany, VRX N.Mexico, VRX.Switzerland, 0QYW.UK,
Valeant Pharmaceuticals International Inc was formed under the Business Corporations Act (Ontario) on February 18, 2000, as a result of the amalgamation of TXM Corporation and Biovail Corporation International. Biovail was continued under the Canada Business Corporations Act effective June 29, 2005. In connection with the acquisition of Valeant Pharmaceuticals International (Valeant) in September 2010, Biovail was renamed Valeant Pharmaceuticals International, Inc. It is a multinational, specialty pharmaceutical and medical device company that develops, manufactures, and markets a range of branded, generic and branded generic pharmaceuticals, over-the-counter products OTC, and medical devices such as contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices, which are marketed directly or indirectly in over 100 countries. The Company operates in two segments; Developed Markets and Emerging Markets. In the Developed Markets segment, it focuses its efforts in the eye health, dermatology, and neurology therapeutic classes. The Developed Markets segment consists of four reporting units based on geography, namely; U.S., Canada and Australia, Western Europe, and Japan. In the Emerging Markets segment, it focuses on branded generics, OTC products, and medical devices. The Emerging Markets segment consists of three reporting units based on geography, namely; Central & Eastern Europe, Middle East and North Africa, Latin America, and Asia & South Africa. Its principal pharmaceutical products are; Wellbutrin XL, Xenazine, Zovirax Cream, Zovirax, Lotemax, Arestin and Prolensa. Its principal OTC products are; PreserVision, ReNu Multiplus, Ocuvite, Artelac, and CeraVe. The Company relies on a combination of contractual provisions, confidentiality policies and procedures and patent, trademark, copyright and trade secrecy laws to protect the proprietary aspects of its technology and business. Its top four geographic markets are; the U.S. and Puerto Rico, Canada, Poland and Russia. The Company competes with specialty and other pharmaceutical companies, medical device companies, biotechnology companies, OTC companies and generic manufacturers, in the U.S., Canada, the EU and in other countries in which it market its products. The principal raw materials, including active pharmaceutical ingredient, used by the Company "or its third party manufacturers" for its various products are purchased in the open market or are otherwise available from several sources. The Company is subject to extensive U.S. federal and state health care marketing and fraud and abuse regulations, such as the federal False Claims Act, federal and provincial marketing regulation in Canada and similar regulations in foreign countries in which it may conduct its business.
» More Articles for NYSE:VRX

Headlines

Articles On GuruFocus.com
Mandel’s Lone Pine Takes Stake in Growing Horizon Pharma Jul 28 2015 
Gabelli ABC Fund Second Quarter Letter Jul 27 2015 
Acquisition in the Health Care Industry Increased Volatility Jun 27 2015 
Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
Andreas Halvorsen Sells More Than Half of His Stake in Valeant Jun 18 2015 
My Top 3 Pharma Stock Picks Jun 09 2015 
Lou Simpson Adds Precision Castparts to Portfolio in First Quarter Jun 08 2015 
Jeff Ubben Adds to Stakes in Microsoft, Halliburton, Baker Hughes in First Quarter Jun 04 2015 
An Exclusive GuruFocus Interview With Value Investor Wally Weitz Jun 03 2015 
John Paulson's First-Quarter Moves Alter Largest And Most Valuable Stakes Jun 01 2015 

More From Other Websites
VALEANT PHARMACEUTICALS INTERNATIONAL, INC. Files SEC form 10-Q, Quarterly Report Jul 28 2015
Which Big-Cap Stocks Are Defying Market Pressure? Jul 27 2015
Morgan Stanley Lifts Target On Valeant From $235 To $284 Jul 27 2015
RedHill Biopharma Provides Update on RHB-106 Program Partnered with Salix Pharmaceuticals Jul 27 2015
Valeant, Starbucks Lead 5 IBD 50 Stocks Bucking Market Jul 24 2015
Biogen's Big-Volume Plunge Marks End Of 5-Year Run Jul 24 2015
Valeant (VRX) Beats on Q2 Earnings & Revenues, Ups View - Analyst Blog Jul 24 2015
Valeant Clears Buy Point, Paces Top Medical Stocks Jul 23 2015
3 Big-Cap Drugmakers Who Beat Q2 Earnings Estimates Jul 23 2015
Stock Market Today - 07/23/15 Jul 23 2015
Dealpolitik: Activism Makes Corporate Governance More Complex at Zoetis Jul 23 2015
Valeant Pharmaceuticals (VRX) Earnings Report: Q2 2015 Conference Call Transcript Jul 23 2015
Valeant 2Q results beat estimates sending stock up Jul 23 2015
Valeant 2Q results beat estimates sending stock up Jul 23 2015
Valeant Passes RBC as Canada’s Largest Company by Market Value Jul 23 2015
Valeant Pharmaceuticals: All That Deal Making Pays Off? Jul 23 2015
Valeant profit beats estimates as U.S. sales stay strong Jul 23 2015
Valeant Earnings Soar On M&A, Organic Sales Growth Jul 23 2015
Valeant Ups Views With Big Quarter Jul 23 2015
Valeant reports 2Q loss Jul 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK